JP2011506588A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011506588A5 JP2011506588A5 JP2010538886A JP2010538886A JP2011506588A5 JP 2011506588 A5 JP2011506588 A5 JP 2011506588A5 JP 2010538886 A JP2010538886 A JP 2010538886A JP 2010538886 A JP2010538886 A JP 2010538886A JP 2011506588 A5 JP2011506588 A5 JP 2011506588A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- independently
- formula
- cancer
- solvates
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 48
- 238000000034 method Methods 0.000 claims 30
- 150000003839 salts Chemical class 0.000 claims 20
- 239000012453 solvate Substances 0.000 claims 20
- 150000004677 hydrates Chemical class 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 238000004519 manufacturing process Methods 0.000 claims 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 239000007810 chemical reaction solvent Substances 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- VSTXCZGEEVFJES-UHFFFAOYSA-N 1-cycloundecyl-1,5-diazacycloundec-5-ene Chemical group C1CCCCCC(CCCC1)N1CCCCCC=NCCC1 VSTXCZGEEVFJES-UHFFFAOYSA-N 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 208000032612 Glial tumor Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 125000001931 aliphatic group Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 2
- 150000007530 organic bases Chemical class 0.000 claims 2
- 230000020477 pH reduction Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- LNNXOEHOXSYWLD-UHFFFAOYSA-N 1-bromobut-2-yne Chemical group CC#CCBr LNNXOEHOXSYWLD-UHFFFAOYSA-N 0.000 claims 1
- GAPRPFRDVCCCHR-UHFFFAOYSA-N 3-bromoprop-1-ynyl(trimethyl)silane Chemical group C[Si](C)(C)C#CCBr GAPRPFRDVCCCHR-UHFFFAOYSA-N 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 230000006369 cell cycle progression Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 230000000269 nucleophilic effect Effects 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 239000011541 reaction mixture Substances 0.000 claims 1
- 230000035484 reaction time Effects 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1452007P | 2007-12-18 | 2007-12-18 | |
| PCT/GB2008/004140 WO2009077741A2 (en) | 2007-12-18 | 2008-12-16 | 3-substituted-4-oxo-3,4-dihydro-imidazo-[5,1-d][1,2,3,5-tetrazine-8-carboxylic acid amides and their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011506588A JP2011506588A (ja) | 2011-03-03 |
| JP2011506588A5 true JP2011506588A5 (enExample) | 2012-02-09 |
Family
ID=40427129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010538886A Pending JP2011506588A (ja) | 2007-12-18 | 2008-12-16 | 抗がん剤としての３−置換−４−オキソ−３，４−ジヒドロ−イミダゾ−［５，１−ｄ］［１，２，３，５］−テトラジン−８−カルボン酸アミド |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US8450479B2 (enExample) |
| EP (2) | EP2698370A3 (enExample) |
| JP (1) | JP2011506588A (enExample) |
| CN (1) | CN101945874A (enExample) |
| AR (1) | AR071548A1 (enExample) |
| AU (1) | AU2008337261A1 (enExample) |
| CA (1) | CA2709749A1 (enExample) |
| IL (1) | IL206453A0 (enExample) |
| PE (1) | PE20091101A1 (enExample) |
| TW (1) | TW200934782A (enExample) |
| WO (1) | WO2009077741A2 (enExample) |
| ZA (1) | ZA201004554B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20091101A1 (es) | 2007-12-18 | 2009-07-26 | Pharminox Ltd | AMIDAS DE ACIDO 3-SUBSTITUIDO-4-OXO-3,4-DIHIDRO-IMIDAZO[5,1-d] [1,2,3,5-TETRACINA-8-CARBOXILICO Y SU EMPLEO |
| US9024018B2 (en) * | 2009-06-23 | 2015-05-05 | Pharminox Limited | 3-substituted-8-substituted-3H-imidazo[5,1-d][1,2,3,5]tetrazin-4-one compounds and their use |
| WO2011107726A1 (en) | 2010-03-01 | 2011-09-09 | Pharminox Ltd | Methods and intermediates for the synthesis of 4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5]tetrazines |
| WO2012085501A1 (en) | 2010-12-20 | 2012-06-28 | Pharminox Limited | 8 - sulfo - imidazotetrazin- 4 - one compounds and their use as anticancer drug |
| RU2545458C2 (ru) * | 2013-08-01 | 2015-03-27 | Автономная Некоммерческая Организация "Научно-Исследовательский Центр Биотехнологии Антибиотиков И Других Биологически Активных Веществ "Биоан" | ПРОТИВОТУБЕРКУЛЕЗНОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО: КОМПОЗИЦИЯ ИМИДАЗО[1,2-b]ТЕТРАЗИНА С ПИРАЗИНАМИДОМ |
| CN108276415B (zh) * | 2018-02-08 | 2019-07-05 | 台州职业技术学院 | 一种烷氧化三唑并四嗪类化合物及其制备方法和应用 |
| BR112021002293A2 (pt) | 2018-08-09 | 2021-05-04 | The Board Of Trustees Of The University Of Illinois | compostos de imidazotetrazina |
| WO2020106558A1 (en) | 2018-11-20 | 2020-05-28 | Merck Sharp & Dohme Corp. | Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use |
| WO2020106560A1 (en) | 2018-11-20 | 2020-05-28 | Merck Sharp & Dohme Corp. | Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use |
| PE20211768A1 (es) | 2018-11-30 | 2021-09-07 | Merck Sharp & Dohme | Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmaceuticas y su uso |
| JP2022511778A (ja) | 2018-11-30 | 2022-02-01 | メルク・シャープ・アンド・ドーム・コーポレーション | アデノシン受容体拮抗薬としての７－、８－及び１０－置換されたアミノトリアゾロキナゾリン誘導体、医薬組成物及びそれらの使用 |
| GB201907813D0 (en) | 2019-05-31 | 2019-07-17 | Univ Nottingham | Therapeutic compounds |
| KR102571751B1 (ko) | 2020-03-24 | 2023-08-25 | 삼성에스디아이 주식회사 | 리튬 이차 전지의 전해질용 첨가제, 리튬 이차 전지용 전해질 및 이를 포함하는 리튬 이차 전지 |
| WO2022266468A1 (en) * | 2021-06-18 | 2022-12-22 | Yale University | Anti-cancer compounds and methods of use |
| US20240400572A1 (en) * | 2021-09-23 | 2024-12-05 | Yale University | Compounds and methods for treating cancers that are mgmt deficient regardless of mmr status |
| US20250129083A1 (en) * | 2022-02-01 | 2025-04-24 | The Board Of Trustees Of The University Of Illinois | Imidazotetrazine compounds and treatment of tmz-resistant cancers |
| TW202515538A (zh) * | 2023-08-04 | 2025-04-16 | 美商莫迪菲生物科學有限公司 | 氟烷氧基伸烷基－二氫咪唑并〔５，１－ｄ〕四嗪酮化合物及相關化合物以及其在治療醫學疾患中之用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| OA07174A (fr) | 1981-08-24 | 1984-04-30 | May & Baker Ltd | Nouvelles imidazotétrazionones, leur préparation et les médicaments qui les contiennent. |
| US5260291A (en) * | 1981-08-24 | 1993-11-09 | Cancer Research Campaign Technology Limited | Tetrazine derivatives |
| GB2125402B (en) | 1982-08-17 | 1985-11-13 | May & Baker Ltd | New tetrazine derivatives |
| US4504475A (en) | 1983-05-24 | 1985-03-12 | Warner Lambert Company | 3-(Haloethyl)-4-oxopyrazolo[5,1-D]-1,2,3,5-tetrazine-8-carboxamide compounds |
| GB9504361D0 (en) | 1995-03-04 | 1995-04-26 | Glaxo Spa | Heterocyclic compounds |
| AR035419A1 (es) | 2001-01-18 | 2004-05-26 | Schering Corp | Un proceso para preparar compuestos imidazo-tetrazin-4-ona, compuestos intermediarios, sales de adicion de acidos, un proceso para preparar la temozolomida, un proceso para preparar intermediarios |
| CN1742723A (zh) | 2004-09-02 | 2006-03-08 | 天津倍方科技发展有限公司 | 含有替莫唑胺－8－羧酸酯的药物组合物以及该类化合物用于制备抗肿瘤药物的用途 |
| PE20091101A1 (es) | 2007-12-18 | 2009-07-26 | Pharminox Ltd | AMIDAS DE ACIDO 3-SUBSTITUIDO-4-OXO-3,4-DIHIDRO-IMIDAZO[5,1-d] [1,2,3,5-TETRACINA-8-CARBOXILICO Y SU EMPLEO |
| GB0807103D0 (en) | 2008-04-18 | 2008-05-21 | Univ Bradford The | Compounds |
| US9024018B2 (en) | 2009-06-23 | 2015-05-05 | Pharminox Limited | 3-substituted-8-substituted-3H-imidazo[5,1-d][1,2,3,5]tetrazin-4-one compounds and their use |
-
2008
- 2008-12-12 PE PE2008002071A patent/PE20091101A1/es not_active Application Discontinuation
- 2008-12-16 EP EP20130175051 patent/EP2698370A3/en not_active Withdrawn
- 2008-12-16 WO PCT/GB2008/004140 patent/WO2009077741A2/en not_active Ceased
- 2008-12-16 JP JP2010538886A patent/JP2011506588A/ja active Pending
- 2008-12-16 EP EP08861839A patent/EP2229393A2/en not_active Withdrawn
- 2008-12-16 CA CA2709749A patent/CA2709749A1/en not_active Abandoned
- 2008-12-16 AU AU2008337261A patent/AU2008337261A1/en not_active Abandoned
- 2008-12-16 CN CN2008801269450A patent/CN101945874A/zh active Pending
- 2008-12-16 US US12/808,604 patent/US8450479B2/en not_active Expired - Fee Related
- 2008-12-18 TW TW097149411A patent/TW200934782A/zh unknown
- 2008-12-18 AR ARP080105534A patent/AR071548A1/es unknown
-
2010
- 2010-06-17 IL IL206453A patent/IL206453A0/en unknown
- 2010-06-28 ZA ZA2010/04554A patent/ZA201004554B/en unknown
-
2013
- 2013-05-24 US US13/901,680 patent/US20130338104A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011506588A5 (enExample) | ||
| JP2020533288A5 (enExample) | ||
| JP2017504576A5 (enExample) | ||
| RU2014131065A (ru) | Димерные соединения-агонисты рецептора fgf ( fgfr ), способ их получения и их терапевтическое применение | |
| JP2017526726A5 (enExample) | ||
| JP2017518959A5 (enExample) | ||
| JP2011509949A5 (enExample) | ||
| JP2012082227A5 (enExample) | ||
| JP2016512823A5 (enExample) | ||
| CA2953472C (en) | Halogen-substituted heterocyclic compound salt | |
| JP2018513832A5 (enExample) | ||
| JP2013521301A5 (enExample) | ||
| JP7044281B2 (ja) | チエノ環系化合物およびその合成方法と応用 | |
| JP2015508092A5 (enExample) | ||
| RU2010119458A (ru) | 1,3,5-тризамещенное производное триазола | |
| JP7446460B2 (ja) | 新規ｅｐ４拮抗薬の合成及びその癌及び炎症における使用 | |
| JP2021509683A (ja) | ピリジルイミダゾベンゾジアゼピンプロピオン酸エステル化合物およびその合成と使用 | |
| RU2010113358A (ru) | Гуанидинсодержащие соединения, применимые в качестве антагонистов мускариновых рецепторов | |
| JP2015502371A5 (enExample) | ||
| RU2017132330A (ru) | Соли производного хиназолина и способ их получения | |
| KR20200055126A (ko) | Ａ2ａ수용체 억제제로서의 축합 고리 유도체 | |
| JP2024530111A (ja) | アフィカムテンを調製するための工程 | |
| AU2024252230A1 (en) | Synthesis of ras inhibitors | |
| JP2022539126A (ja) | ベンゾジアゼピン系化合物及びその製造方法並びに医薬における作用 | |
| JP2019509295A (ja) | レチノイン酸系化合物、その製造方法、中間体及び応用 |